SYGNIS AG

euro adhoc: Sygnis Pharma AG
Restructuring & Recapitalisations
SYGNIS Pharma AG Approves Capital Increase

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

15.10.2008

SYGNIS Pharma AG Approves Capital Increase

Heidelberg, October 15, 2008 - Today the Management Board of the Heidelberg biotechnology company SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) with the consent of the Supervisory Board approved an increase of the company's share capital of EUR 28,563,676.00 by EUR 12,694,967.00 to EUR 41,258,643.00 by means of the issuance of 12,694,967 shares of common bearer stock without nominal value from authorized capital. The new shares will be subscribed to by Sal. Oppenheim jr. & Cie KGaA, Frankfurt am Main ("Sal. Oppenheim") subject to the requirement that it will offer the shares for purchase to the company shareholders. As the shareholders' subscription rights are secured the shareholders can subscribe to the new shares, which will include  dividend participation rights starting April 01, 2008, at a ratio of 9:4 during the period commencing October 21, 00:00 Central European Summer Time and ending November 04, 2008, 12:00 pm (noon) Central European Time at a subscription price of EUR 1.44 per new share. It may also be possible to subscribe to additional new shares. The new shares will not be offered in a public offering. The new shares will have full profit participation rights for the fiscal year starting April 1, 2008. The listing of the new shares will occur at a later date. Further details on the capital increase will be contained in the subscription offer which is expected to be published in the electronic Bundesanzeiger on October 20, 2008. The major shareholders dievini Hopp BioTech holding GmbH & Co. KG and BASF SE have committed to Sal. Oppenheim jr. & Cie. KGaA to fully exercise the subscription rights to which they are entitled by virtue of their share ownership. They have further committed to Sal. Oppenheim jr. & Cie. KGaA to acquire all new shares that are not subscribed to by other shareholders at the subscription price. The company will use the total net proceeds which are expected to be more than EUR 18 million for the clinical development of AX200 for use in the treatment of acute stroke, the further development of the existing project pipeline and the expansion of the pipeline by new projects. This notice is for information purposes only, and does not constitute an offer for the sale of or a solicitation of offers for the purchase of subscription rights or securities in the United States of America (USA), Germany, or any other jurisdiction. Subscription rights and securities may not be offered or sold without registration or an exemption from the registration requirement under the US Securities Act of 1933 as amended and the securities laws of the individual US states. SYGNIS Pharma AG does not intend to register any portion of this offer in the USA or to make a public offering of subscription rights or securities.

For further information, please contact:

Dr. Franz-Werner Haas VP Operations / General Counsel Tel: +49 (0) 6221-454 812 Email: franz-werner.haas@sygnis.de

###

Certain statements contained in this press release, which are neither documented financial results or other historical data, are prospective in nature. This refers in particular to prognoses of future events, trends, plans, or goals. Such statements must not be considered absolutely certain, as they are by their nature subject to known and unknown risks, and can be influenced by other factors, as a result of which the actual results, plans, and goals of SYGNIS may substantially differ from the express or implied forward-looking statements. SYGNIS undertakes no obligation to publicly update or revise these statements, either in the light of new information or future events, or for other reasons. ###

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: LION Bioscience AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Simone Angstmann
Executive Assistant
Telefon: +49(0)6221 454-852
E-Mail: simone.angstmann@sygnis.de

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX
Börsen:  Börse Frankfurt / regulated dealing/prime standard
              Börse Berlin / free trade
              Börse Hamburg / free trade
              Börse Stuttgart / free trade
              Börse Düsseldorf / free trade
              Börse Hannover / free trade
              Börse München / free trade



Das könnte Sie auch interessieren: